Two years ago, pharmaceutical giant, Roche, promised the BMJ to release key Tamiflu trial data for an independent investigation. However, Roche refuses to provide full access to all its data. According to a new report by the Cochrane Collaboration, Roche's refusal to provide access leaves critical concerns about how the drug works unresolved.
A BMJ investigation, published at the same time as the report, also voices serious concerns regarding drug data access, the drug approval process and the use of ghostwriters in drug trials. More
No comments:
Post a Comment